HeartSciences Granted European Patent for Electrode, Cable Connections

The European Patent Office has granted Heart Test Laboratories Inc. d/b/a HeartSciences a patent to cover the design of its electrode and cable connectors used with an ECG and its MyoVista device. 
 
“Millions of ECGs are performed every week. The electrodes used with the MyoVista® are proprietary to HeartSciences. Adding Europe to our electrode patent coverage strengthens and diversifies our overall intellectual property portfolio as well as further protects future recurring revenues. This granted patent enhances our strategic position as we progress toward commercialization,” HeartSciences CEO Andrew Simpson said. “Unlike a conventional ECG, the MyoVista AI algorithm for cardiac dysfunction analyzes frequency signals from the heart. Our electrode design helps ensure an optimal, high quality, low impedance signal capture for each and every test. We have secured a number of U.S. and international patents and this most recent expansion of our IP portfolio is an example of how we continue to leverage our first mover advantage as we position ourselves to deliver a new era of clinical value for ECGs across the U.S. and internationally.”  

Electrocardiography (ECG) systems analyze the electrical activity of the heart by recording and processing electrical signals using electrodes placed on a patient’s body. HeartSciences’ first product candidate for U.S. Food and Drug Administration clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The business model, which involves the use of the MyoVista device and consumables for each test, is expected to be “razor-razorblade” as the electrodes used with the MyoVista are proprietary to HeartSciences, and new electrodes are required for every test performed.
 
HeartSciences is focused on applying AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG’s clinical usefulness. Millions of ECGs are performed every week and the company’s objective is to improve healthcare by making an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.